Sinografin
- Generic Name: diatrizoate meglumine and iodipamide meglumine injection
- Brand Name: Sinografin
Sinografin (Diatrizoate Meglumine and Iodipamide Meglumine Injection) side effects drug center
- Related Drugs
- Health Resources
- hypersensitivity reactions (sweating, flushing, itching, hives, skin rashes, joint pain, respiratory distress, and circulatory collapse)
- dizziness,
- fainting,
- low blood pressure (hypotension),
- chills,
- fever,
- nausea,
- vomiting,
- and abdominal pain and tenderness.
Sinografin (diatrizoate meglumine and lodipamide meglumine injection) is a radiopaque contrast medium for intrauterine instillation indicated for use in hysterosalpingography. Common side effects of Sinografin include:
The dosage of Sinografin is 3 to 4 mL, administered in fractional doses of approximately 1 mL, are usually adequate to visualize the uterus; an additional 3 to 4 mL will demonstrate the tubes. Sinografin may interact with other drugs. Tell your doctor all medications and supplements you use. Use of Sinografin is not recommended in women who are pregnant or who suspect they may be pregnant. Sinografin passes into breast milk. Consult your doctor before breastfeeding.
Our Sinografin (diatrizoate meglumine and lodipamide meglumine injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Sinografin Professional Information
SIDE EFFECTS
Sudden onset of bradycardia, hypotension, cardiac arrest and death have rarely been reported.
Hypersensitivity reactions, which include sweating, flushing, pruritus, urticaria, skin rashes, arthralgia, respiratory distress, and circulatory collapse have occurred. Dizziness, syncope, hypotension, chills, fever, nausea, vomiting, and abdominal pain and tenderness are occasionally seen following instillation of the contrast medium.
It should be kept in mind that the serious or anaphylactoid reactions that may occur with intravascular administration of radiopaque contrast agents are theoretically possible following administration by other routes.
Read the entire FDA prescribing information for Sinografin (Diatrizoate Meglumine and Iodipamide Meglumine Injection)